A Study to Evaluate the Dosing of AMG 827 for Subjects With Inadequately Controlled Asthma
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Determine the Safety and Efficacy of AMG 827 in Subjects With Inadequately Controlled Asthma
Descripción general del estudio
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 2
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Feldbach, Austria
- Research Site
-
Hallein, Austria
- Research Site
-
Wien, Austria
- Research Site
-
-
-
-
-
Bruxelles, Bélgica
- Research Site
-
Leuven, Bélgica
- Research Site
-
Liege, Bélgica
- Research Site
-
-
-
-
Alberta
-
Calgary, Alberta, Canadá
- Research Site
-
-
Ontario
-
Ottawa, Ontario, Canadá
- Research Site
-
Toronto, Ontario, Canadá
- Research Site
-
-
-
-
-
Bucheon-si, Corea, república de
- Research Site
-
Seoul, Corea, república de
- Research Site
-
Suwon, Corea, república de
- Research Site
-
-
-
-
California
-
Encinitas, California, Estados Unidos
- Research Site
-
Huntington Beach, California, Estados Unidos
- Research Site
-
Los Angeles, California, Estados Unidos
- Research Site
-
San Diego, California, Estados Unidos
- Research Site
-
Stockton, California, Estados Unidos
- Research Site
-
-
Colorado
-
Colorado Springs, Colorado, Estados Unidos
- Research Site
-
-
Georgia
-
Stockbridge, Georgia, Estados Unidos
- Research Site
-
-
Maryland
-
Baltimore, Maryland, Estados Unidos
- Research Site
-
-
Massachusetts
-
North Dartmouth, Massachusetts, Estados Unidos
- Research Site
-
-
Missouri
-
Saint Louis, Missouri, Estados Unidos
- Research Site
-
-
Montana
-
Bozeman, Montana, Estados Unidos
- Research Site
-
-
Nebraska
-
Bellevue, Nebraska, Estados Unidos
- Research Site
-
-
New Jersey
-
Skillman, New Jersey, Estados Unidos
- Research Site
-
-
New York
-
Rockville Centre, New York, Estados Unidos
- Research Site
-
-
North Carolina
-
High Point, North Carolina, Estados Unidos
- Research Site
-
-
Ohio
-
Cincinnati, Ohio, Estados Unidos
- Research Site
-
-
Oregon
-
Lake Oswego, Oregon, Estados Unidos
- Research Site
-
Medford, Oregon, Estados Unidos
- Research Site
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Estados Unidos
- Research Site
-
-
Texas
-
Dallas, Texas, Estados Unidos
- Research Site
-
El Paso, Texas, Estados Unidos
- Research Site
-
-
Wisconsin
-
Madison, Wisconsin, Estados Unidos
- Research Site
-
-
-
-
-
Moscow, Federación Rusa
- Research Site
-
Saint Petersburg, Federación Rusa
- Research Site
-
-
-
-
-
Helsinki, Finlandia
- Research Site
-
Jyväskylä, Finlandia
- Research Site
-
Turku, Finlandia
- Research Site
-
-
-
-
-
Edeleny, Hungría
- Research Site
-
Matrahaza, Hungría
- Research Site
-
Tatabanya, Hungría
- Research Site
-
Torokbalint, Hungría
- Research Site
-
Zalaegerszeg - Pozva, Hungría
- Research Site
-
-
-
-
-
Rotterdam, Países Bajos
- Research Site
-
-
-
-
-
Bialystok, Polonia
- Research Site
-
Chodziez, Polonia
- Research Site
-
Gdansk, Polonia
- Research Site
-
Wroclaw, Polonia
- Research Site
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Men or women 18 to 65 years of age
- Percent of predicted FEV1 ≥ 50% and ≤ 80%
- At least 12% reversibility over pre-bronchodilator FEV1
- Inhaled corticosteroid (ICS) ≥ 200 and ≤ 1000 µg/day fluticasone powder or equivalent
- Ongoing asthma symptoms with ACQ composite score ≥ 1.5 points
Exclusion Criteria:
- Respiratory infection within 4 weeks of screening visit or 1 week of baseline visit
- History of chronic obstructive pulmonary disease or other chronic pulmonary condition other than asthma
- Any uncontrolled or clinically significant systemic disease (eg, uncontrolled diabetes, liver disease)
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Doble
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Comparador de placebos: Placebo
Participants will receive the matching placebo administered as subcutaneous (SC) injections at Day 1 and weeks 1, 2, 4, 6, 8, and 10.
|
Inyección subcutánea.
|
|
Experimental: AMG 827 140 mg
Participants will receive AMG 140 mg administered as SC injections at Day 1 and weeks 1, 2, 4, 6, 8, and 10.
|
SC injection.
|
|
Experimental: AMG 827 210 mg
Participants will receive AMG 210 mg administered as SC injections at Day 1 and weeks 1, 2, 4, 6, 8, and 10.
|
SC injection.
|
|
Experimental: AMG 827 280 mg
Participants will receive AMG 280 mg administered as SC injections at Day 1 and weeks 1, 2, 4, 6, 8, and 10.
|
SC injection.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change From Baseline in Asthma Control Questionnaire (ACQ) Composite Scores to Week 12
Periodo de tiempo: Baseline and Week 12
|
The ACQ is an instrument used in clinical research and practice to evaluate asthma control/impairment. It is a validated composite score that assesses disease control by evaluating 7 questions: night time awakenings, asthma symptoms upon awakening, activity limitation, shortness of breath, wheeze frequency, short-acting bronchodilator use, and forced expiratory volume in 1 second (FEV1). The response options for all these questions range from zero (no impairment/limitation) to six (total impairment/limitation) scale. The total score is obtained by adding the value from each question and dividing by the number of questions. Higher scores indicates worsening of condition and a negative change from baseline indicates improvement. |
Baseline and Week 12
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change From Baseline in Pre- and Post-Bronchodilator Forced Expiratory Volume in 1 Second (FEV1)
Periodo de tiempo: Baseline and Week 12
|
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
FEV1 was performed both pre and post-administration of bronchodilator treatment at Baseline and Week 12.
|
Baseline and Week 12
|
|
Change From Baseline in AM and PM Peak Expiratory Flow Rate (PEFR) to Week 12
Periodo de tiempo: Baseline and Week 12
|
Baseline and Week 12
|
|
|
Change From Baseline in the Frequency of Rescue Short Acting β-Agonist (SABA) Use to Week 12
Periodo de tiempo: Baseline to Week 12
|
Participants recorded SABA use for 1 week prior to randomization (baseline) and the average number of days recorded was subtracted from average days of SABA use across 12 week intervention period.
|
Baseline to Week 12
|
|
Change From Baseline in Daily Asthma Symptom Score to Week 12
Periodo de tiempo: Baseline and Week 12
|
Participants recorded their daily asthma symptoms in their electronic diaries (Ediary). It included 7 questions: frequency of night time awakening, time awake at night, wheezing, shortness of breath, cough, chest tightness and activity limitation. Daily asthma symptoms score is the sum of 7 individual scores (with the total score ranging from 0-21). Higher scores indicates worsening of condition and a negative change from baseline indicates improvement. |
Baseline and Week 12
|
|
Change From Baseline in Asthma Quality of Life Questionnaire (AQLQ) Score at Week 12
Periodo de tiempo: Baseline and Week 12
|
The AQLQ is the most commonly used asthma specific instrument and includes evaluations of both symptom and quality of life measures. The 32-item instrument measures 4 domains affected by asthma including activity limitations, emotional function, exposure to environmental stimuli, and symptoms (Mitchell EA et al, 1997, Juniper et al, 1994, Christie MJ et al, 1993, Juniper et al, 1993). Participants were asked to recall their experiences during the last 2 weeks and to respond to each question on a 7-point scale (7=no impairment, 1=severe impairment). The overall score = mean of the responses to the 32 questions. Higher scores indicate "better quality of life" and a positive change from baseline indicates improved symptoms. |
Baseline and Week 12
|
|
Proportion of Asthma Symptom-free Days
Periodo de tiempo: Up to Week 12
|
Asthma symptom-free days were defined as a participant having a score of zero in their daily asthma symptom score. Asthma symptom-free days without SABA use were defined as a participant having a score of zero in their daily asthma symptom score and no SABA use. The proportion of asthma symptom-free days was calculated as the number of asthma symptom-free days over the number of days in the double-blind treatment period (12 weeks). |
Up to Week 12
|
|
Time to Maximum Observed Concentration (Tmax) of AMG 827 at Week 8 to 10
Periodo de tiempo: Week 8 (days 60 and 64), and pre-dose on Week 10
|
Week 8 (days 60 and 64), and pre-dose on Week 10
|
|
|
Maximum Observed Concentration (Cmax) of AMG 827 at Week 8 to 10
Periodo de tiempo: Week 8 (days 60 and 64), and pre-dose on Week 10
|
Week 8 (days 60 and 64), and pre-dose on Week 10
|
|
|
Area Under the Concentration-time Curve During the Dosing Interval (AUCtau) of AMG 827 at Week 8 to 10
Periodo de tiempo: Week 8 (days 60 and 64), and pre-dose on Week 10
|
Week 8 (days 60 and 64), and pre-dose on Week 10
|
Colaboradores e Investigadores
Patrocinador
Publicaciones y enlaces útiles
Enlaces Útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 20090203
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .